322 related articles for article (PubMed ID: 33343580)
1. Broad Neutralization Responses Against Oncogenic Human Papillomaviruses Induced by a Minor Capsid L2 Polytope Genetically Incorporated Into Bacterial Ferritin Nanoparticles.
Yang F; Mariz FC; Zhao X; Spagnoli G; Ottonello S; Müller M
Front Immunol; 2020; 11():606569. PubMed ID: 33343580
[TBL] [Abstract][Full Text] [Related]
2. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
[TBL] [Abstract][Full Text] [Related]
3. A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2.
Tumban E; Peabody J; Peabody DS; Chackerian B
PLoS One; 2011; 6(8):e23310. PubMed ID: 21858066
[TBL] [Abstract][Full Text] [Related]
4. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
[TBL] [Abstract][Full Text] [Related]
5. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
[TBL] [Abstract][Full Text] [Related]
6. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
[TBL] [Abstract][Full Text] [Related]
7. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20 -- 38) peptide displayed on bacterial thioredoxin.
Rubio I; Bolchi A; Moretto N; Canali E; Gissmann L; Tommasino M; Müller M; Ottonello S
Vaccine; 2009 Mar; 27(13):1949-56. PubMed ID: 19368776
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
10. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
11. Lipidated L2 epitope repeats fused with a single-chain antibody fragment targeting human FcγRI elicited cross-neutralizing antibodies against a broad spectrum of human papillomavirus types.
Zhang T; Liu H; Chen X; Wang Z; Wang S; Qu C; Zhang J; Xu X
Vaccine; 2016 Nov; 34(46):5531-5539. PubMed ID: 27729176
[TBL] [Abstract][Full Text] [Related]
12. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
[TBL] [Abstract][Full Text] [Related]
13. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
14. Durable immunity to oncogenic human papillomaviruses elicited by adjuvanted recombinant Adeno-associated virus-like particle immunogen displaying L2 17-36 epitopes.
Jagu S; Karanam B; Wang JW; Zayed H; Weghofer M; Brendle SA; Balogh KK; Tossi KP; Roden RBS; Christensen ND
Vaccine; 2015 Oct; 33(42):5553-5563. PubMed ID: 26382603
[TBL] [Abstract][Full Text] [Related]
15. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
16. Displaying 31RG-1 peptide on the surface of HPV16 L1 by use of a human papillomavirus chimeric virus-like particle induces cross-neutralizing antibody responses in mice.
Chen X; Zhang T; Liu H; Hao Y; Liao G; Xu X
Hum Vaccin Immunother; 2018; 14(8):2025-2033. PubMed ID: 29683766
[TBL] [Abstract][Full Text] [Related]
17. Broadly neutralizing antiviral responses induced by a single-molecule HPV vaccine based on thermostable thioredoxin-L2 multiepitope nanoparticles.
Spagnoli G; Pouyanfard S; Cavazzini D; Canali E; Maggi S; Tommasino M; Bolchi A; Müller M; Ottonello S
Sci Rep; 2017 Dec; 7(1):18000. PubMed ID: 29269879
[TBL] [Abstract][Full Text] [Related]
18. Targeting synthetic Human Papillomavirus (HPV) L2 disulfide-induced N-terminus conformational epitopes for pan-HPV vaccine development.
Khanal S; Ferraris ED; Zahin M; Joh J; Ghim SJ; Jenson AB
Exp Mol Pathol; 2015 Oct; 99(2):330-4. PubMed ID: 26134615
[TBL] [Abstract][Full Text] [Related]
19. Natural variants in the major neutralizing epitope of human papillomavirus minor capsid protein L2.
Seitz H; Schmitt M; Böhmer G; Kopp-Schneider A; Müller M
Int J Cancer; 2013 Feb; 132(3):E139-48. PubMed ID: 22961598
[TBL] [Abstract][Full Text] [Related]
20. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
